Northway Biotech
KIEL, GERMANY / ACCESSWIRE / May 16, 2023 / tiakis Biotech AG (tiakis), in collaboration with its CDMO partner Northway Biotech, is pleased to announce the successful completion of a technology transfer and ramp-up of manufacturing capabilities for Tiprelestat, a pioneering anti-inflammatory and tissue-protective drug being developed for the prevention of postoperative inflammatory complications following major surgery, treatment of COVID-19 and pulmonary arterial hypertension. For the first time worldwide, a clinical trial is being supported by Tiprelestat study material produced at an industrial fermentation scale, representing a ten-fold increase in manufacturing potential to 3,000 L.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.tiakis Biotech AG and Northway Biotech: Successful Tech Transfer and Expansion of Manufacturing Capabilities for Tiprelestat
"The marked increase in manufacturing capabilities lays the foundation for the next stage of tiakis' development programs, with the recent start of our COMCOVID phase Ib/II clinical trial being a prime example," said Martin Voss, tiakis Biotech AG co-CEO.
The enhanced production capabilities is a result of the successful completion of a technology transfer and subsequent ramp-up program, achieved in a short time through close collaboration with end-to-end biologics CDMO Northway Biotech, based in Vilnius, Lithuania.
Reflecting on this milestone, Vladas Algirdas Bumelis, CEO of Northway Biotech, stated: "The confidence our partners have placed in our two-decade-long expertise has enabled us to collaboratively scale up the process and meet tiakis' deadlines. Our state-of-the-art 3,000 L stainless-steel fermenter train was utilized to carry out the implementation successfully. We extend our sincere well-wishes to our partners as they move forward with their innovative drug through clinical trials, and we look forward to future collaborations."
André Markmann, VP Business Development of Northway Biotech, added: "This partnership exemplifies our commitment to assist our partners in achieving their objectives by leveraging our technical expertise and operational capabilities. We are immensely proud to be part of this groundbreaking project, which addresses a significant unmet medical need."
By attaining this pharmaceutical and technological milestone, tiakis and Northway Biotech have demonstrated their capabilities to pave the way towards groundbreaking achievements as pioneers in their respective fields. The success of this fast-paced project is characterized by strong collaborative interaction, mutual trust, and flexibility between the two companies.
About Tiprelestat
tiakis biopharmaceutical drug candidate Tiprelestat promises an excellent therapeutic benefit-risk profile for use as an anti-inflammatory and tissue-protective drug. Tiprelestat is identical to the human protein elafin with high specificity for tissue-destroying and inflammation-promoting proteases. The development program of Tiprelestat is focused on the late-stage development of Tiprelestat in major surgery and early-stage development in pulmonary arterial hypertension (PAH) and COVID-19.
About tiakis Biotech AG
tiakis focuses on the discovery and development of therapeutic solutions based on its innovative biopharmaceutical Tiprelestat for life-threatening surgeries and life-threatening diseases such as PAH and COVID-19. tiakis seeks partners and investors for the development, commercial-scale manufacturing, marketing and distribution of the product. The company tiakis Biotech AG is located in Kiel, Germany (www.tiakis.bio).
About Northway Biotech
Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and located in Vilnius, Lithuania, London, United Kingdom, and in Waltham, MA, US. Further information can be found on Northway's website www.northwaybiotech.com.
Contact Information
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
SOURCE: Northway Biotech
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/755218/tiakis-Biotech-AG-and-Northway-Biotech-Successful-Tech-Transfer-and-Expansion-of-Manufacturing-Capabilities-for-Tiprelestat
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
SK tes Announces Grand Opening of New Shannon Facility, Marking a Milestone for Sustainable Technology in Ireland22.12.2025 15:00:00 CET | Press release
SHANNON, IE / ACCESS Newswire / December 22, 2025 / SK tes, a global leader in secure technology lifecycle and IT asset disposition (ITAD) services, is delighted to announce the grand opening of its state-of-the-art facility in Shannon, County Clare. The opening event, to be held on Jan. 15, 2026, marks the culmination of a journey that began with the company's announcement in 2025 of its plans to establish a purpose-built facility in one of Ireland's fastest-growing technology regions. The grand opening will be hosted by Jin Mo Lee, SK tes Group CEO at SK tes and guest of honor, Minister Timmy Dooley will cut the ribbon to officially open the site. Minister Dooley, a Clare native, serves as Minister of State for Climate, Energy and the Environment. Minister Dooley's leadership in climate, energy, and environmental policy is especially relevant as Ireland continues to attract major global data center infrastructure and technology companies, while placing increased emphasis on sustainab
Saat & Saat Acquires Turkish Apparel Leader Aydinli Group, Expanding U.S. Polo Assn. Markets Across Turkey, the Middle East, Eastern Europe, and North Africa22.12.2025 13:00:00 CET | Press release
WEST PALM BEACH, FL AND ISTANBUL, TURKEY / ACCESS Newswire / December 22, 2025 / USPA Global is pleased to announce the acquisition of Aydinli Hazir Giyim San. Tic. A.S. (Aydinli Group) by HRK Holding A.S. (Saat & Saat). Both entities are licensing partners of U.S. Polo Assn., which is USPA Global's multi-billion-dollar sports brand and the official brand of the United States Polo Association (USPA). As one of the brand's largest partners, the acquisition of Aydinli provides access to more than 50 countries across Turkey, the Middle East, Eastern Europe, and North Africa. With this acquisition of Aydinli, Saat & Saat is expanding the company's regional portfolio alongside its very successful watch business by entering the global apparel industry. With more than nearly 450 U.S. Polo Assn. stores and multiple branded digital sites, U.S. Polo Assn. will continue its record growth. Aydinli is currently one of the leading retail powerhouses in the region, with significant growth potential a
Parallel Society Reveals Lineup for 2026 Lisbon Edition - A Cross-Genre Mashup of Cultural and Tech Pioneers22.12.2025 10:30:00 CET | Press release
Apparat (live) Kode9, Moses Boyd, Gilles Peterson and Clark head to Lisbon for new indie festival Parallel Society. LISBON, PT / ACCESS Newswire / December 22, 2025 / Parallel Society has revealed the first wave of artists for its 2026 edition in Lisbon, Portugal. The two-day event begins on 6th March, and the music starts on 7th March with a programme spanning the UK jazz revolution (Moses Boyd), experimental bass culture (Kode9, Calibre), avant-electronic (Apparat), and cultural ambassadors (Gilles Peterson), with many more acts still to be announced. A culture-first counterpoint to the corporate consolidation sweeping the global festival landscape, Parallel Society is independent, led by the community, and not for profit. With more than 60% of the lineup sourced from Lisbon's active and diverse homegrown talent pool, the event actively supports the city's underground music scenes. Ahead of Parallel Society's music and cultural programme on Day 2, Day 1, the "[un]conference", invites
Rainer Maria Morita Named "Transformational Leader of the Year 2025" at UK House of Lords22.12.2025 10:25:00 CET | Press release
Recognized for redefining executive career transition and human value creation in the AI era with his globally renowned Morita Method(R) LONDON, GB / ACCESS Newswire / December 22, 2025 / Global executive advisor and bestselling author, Rainer Maria Morita, has been awarded "Transformational Leader of the Year 2025 in the category of Global Hidden Job Market Advisory at the prestigious Global Leadership Conclave 2025, held at the iconic UK House of Lords, Parliament of the United Kingdom. The award recognizes Rainer's pioneering work in redefining leadership, employment, and human value creation in the age of artificial intelligence. With more than two decades of experience across executive search, executive career transition advisory and leadership consulting, Rainer has become a globally respected authority on the Hidden Job Market - the unadvertised ecosystem where over 90% of executive opportunities are created. As the creator of The Morita Method®, Rainer has guided thousands of s
Air T, Inc. Announces Closing of Regional Express Acquisition18.12.2025 23:10:00 CET | Press release
MINNEAPOLIS, MN / ACCESS Newswire / December 18, 2025 / Air T, Inc. (NASDAQ:AIRT) is pleased to announce the successful closing of its acquisition of Regional Express Holdings Limited (Rex), Australia's leading regional airline. Air T now owns 100% of Rex and looks forward to beginning a new chapter for Rex and the regional communities it serves across Australia. The transaction includes a comprehensive financing structure designed to support Rex's operations and future growth: Air T is providing a $50 million AUD credit facility that is funded by one of our investor partners. We anticipate that Rex will use this facility to bring its fleet fully back into service, from approximately 31 flyers currently to 45 flyers within the next two years. The Commonwealth of Australia will continue to be a secured creditor of Rex. Rex will have access to an additional undrawn $60 million AUD loan from the Commonwealth of Australia to support the overhaul of its current fleet of Saab 340s and genera
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom